US equities
|
MU
$878.84
▼-5.63%
NVDA
$214.13
▼-1.43%
TSLA
$354.72
▼-2.13%
AAPL
$343.46
▲+0.43%
META
$709.33
▼-3.72%
MSFT
$529.05
▼-1.93%
SPCX
$146.03
▼-1.74%
AMD
$528.75
▼-5.95%
MU
$878.84
▼-5.63%
NVDA
$214.13
▼-1.43%
TSLA
$354.72
▼-2.13%
AAPL
$343.46
▲+0.43%
META
$709.33
▼-3.72%
MSFT
$529.05
▼-1.93%
SPCX
$146.03
▼-1.74%
AMD
$528.75
▼-5.95%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Articles published by Kronos Bio, Inc.
Kronos Bio Enters into Agreement to Be Acquired by Concentra Biosciences for $0.57 in Cash per Share Plus a Contingent Value Right
May 01, 2025
From
Kronos Bio, Inc.
Via
GlobeNewswire
Tickers
KRON
Kronos Bio Reports Fourth Quarter and Full Year 2024 Financial Results
March 18, 2025
From
Kronos Bio, Inc.
Via
GlobeNewswire
Tickers
KRON
Kronos Bio Announces CEO Transition and Reduction in Force
November 27, 2024
From
Kronos Bio, Inc.
Via
GlobeNewswire
Tickers
KRON
Kronos Bio Highlights Preclinical Data that Show p300 KAT Inhibitors Reduce Inflammation in an Oral Presentation at ACR Convergence 2024
November 14, 2024
From
Kronos Bio, Inc.
Via
GlobeNewswire
Tickers
KRON
Kronos Bio Reports Third Quarter 2024 Financial Results and Corporate Update Including Plan to Evaluate Strategic Alternatives
November 13, 2024
From
Kronos Bio, Inc.
Via
GlobeNewswire
Tickers
KRON
Kronos Bio to Present Data at the ASH Annual Meeting from p300 KAT Inhibition Program in Multiple Myeloma
November 05, 2024
From
Kronos Bio, Inc.
Via
GlobeNewswire
Tickers
KRON
Kronos Bio Data Presentation at EORTC-NCI-AACR Symposium Highlights the Importance of p300 KAT Inhibition in HPV-Driven Tumors
October 23, 2024
From
Kronos Bio, Inc.
Via
GlobeNewswire
Tickers
KRON
Kronos Bio to Present Data at the EORTC-NCI-AACR Symposium that Supports p300 KAT Inhibition in HPV-Driven Tumors
October 09, 2024
From
Kronos Bio, Inc.
Via
GlobeNewswire
Tickers
KRON
Kronos Bio Announces Selection of Autoimmune Development Candidate for Sjögren’s Disease
October 07, 2024
From
Kronos Bio, Inc.
Via
GlobeNewswire
Tickers
KRON
Kronos Bio to Present Data at ACR Convergence 2024 to Support p300 KAT Inhibition as an Approach to Anti-Inflammatory Therapy
September 25, 2024
From
Kronos Bio, Inc.
Via
GlobeNewswire
Tickers
KRON
Kronos Bio Highlights Data at AACR Ovarian Cancer Research Symposium that Supports Clinical Evaluation of Istisociclib in Advanced Ovarian Cancer
September 23, 2024
From
Kronos Bio, Inc.
Via
GlobeNewswire
Tickers
KRON
Kronos Bio Announces Participation in Medical and Investor Conferences in September
September 03, 2024
From
Kronos Bio, Inc.
Via
GlobeNewswire
Tickers
KRON
Kronos Bio Reports Second Quarter 2024 Financial Results and Pipeline Update
August 08, 2024
From
Kronos Bio, Inc.
Via
GlobeNewswire
Tickers
KRON
Kronos Bio Announces First Patient Dosed with KB-0742 in an Expansion Cohort Focused on Platinum-Resistant High-Grade Serous Ovarian Cancer
July 23, 2024
From
Kronos Bio, Inc.
Via
GlobeNewswire
Tickers
KRON
Kronos Bio to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
May 23, 2024
From
Kronos Bio, Inc.
Via
GlobeNewswire
Tickers
KRON
Kronos Bio to Participate in Three Upcoming Healthcare Conferences and Events
May 22, 2024
From
Kronos Bio, Inc.
Via
GlobeNewswire
Tickers
KRON
Kronos Bio Appoints Deborah Knobelman, Ph.D. as Chief Operating Officer and Chief Financial Officer
May 21, 2024
From
Kronos Bio, Inc.
Via
GlobeNewswire
Tickers
KRON
Kronos Bio Reports First-Quarter 2024 Financial Results
May 09, 2024
From
Kronos Bio, Inc.
Via
GlobeNewswire
Tickers
KRON
Kronos Bio to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
April 24, 2024
From
Kronos Bio, Inc.
Via
GlobeNewswire
Tickers
KRON
Kronos Bio Reports Recent Business Progress and Fourth-Quarter and Full-Year 2023 Financial Results
March 21, 2024
From
Kronos Bio, Inc.
Via
GlobeNewswire
Tickers
KRON
Kronos Bio Announces Restructuring to Focus Resources on Clinical Development with Extended Cash Runway
March 07, 2024
From
Kronos Bio, Inc.
Via
GlobeNewswire
Tickers
KRON
Kronos Bio To Present Three Posters at AACR 2024 Annual Meeting
March 05, 2024
From
Kronos Bio, Inc.
Via
GlobeNewswire
Tickers
KRON
Kronos Bio Announces Participation in 44th Annual Cowen Health Care Conference
February 27, 2024
From
Kronos Bio, Inc.
Via
GlobeNewswire
Tickers
KRON
Kronos Bio Implements New Leadership Structure to Drive Pipeline Advancement
January 25, 2024
From
Kronos Bio, Inc.
Via
GlobeNewswire
Tickers
KRON
Kronos Bio Announces Pipeline Update and p300 KAT Inhibitor Development Candidate
December 18, 2023
From
Kronos Bio, Inc.
Via
GlobeNewswire
Tickers
KRON
Kronos Bio Announces Participation in H.C. Wainwright 4th Annual Precision Oncology Virtual Conference
December 04, 2023
From
Kronos Bio, Inc.
Via
GlobeNewswire
Tickers
KRON
Kronos Bio Announces Participation in 35th Annual Piper Sandler Healthcare Conference
November 27, 2023
From
Kronos Bio, Inc.
Via
GlobeNewswire
Tickers
KRON
Kronos Bio Reports Recent Business Progress and Third-Quarter 2023 Financial Results
November 13, 2023
From
Kronos Bio, Inc.
Via
GlobeNewswire
Tickers
KRON
Kronos Bio Announces Plan to Optimize Resource Allocation, Restructure and Contain Costs Following Positive Preliminary Clinical Data from its KB-0742 Phase 1/2 Study
November 02, 2023
From
Kronos Bio, Inc.
Via
GlobeNewswire
Tickers
KRON
Kronos Bio Presents Positive Preliminary Data from the Phase 1 Dose Escalation Portion of the Ongoing Phase 1/2 KB-0742 Study at the Connective Tissue Oncology Society Annual Meeting
November 02, 2023
From
Kronos Bio, Inc.
Via
GlobeNewswire
Tickers
KRON
